Skip to search formSkip to main contentSkip to account menu

EGFR NP_005219.2:p.L858R

Known as: NP_005219.2:p.Leu858Arg, EGFR Leu858Arg, EGFR p.Leu858Arg 
A change in the amino acid residue at position 858 in the epidermal growth factor receptor protein where leucine has been replaced by arginine.
National Institutes of Health

Related topics

Related topics

2 relations
EGFR Gene MutationEGFR NM_005228.3:c.2573_2574delTGinsGT

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Cell-Free DNA Analysis of Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients by Droplet Digital PCR
Cell-free DNA (cfDNA) analysis may provide a non-invasive diagnostic approach for lung adenocarcinoma patients. Recently, droplet… 
2019
2019
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs
The present study assessed whether estrogen receptor (ER)β1 is associated with the survival of patients with advanced lung… 
2017
2017
Abstract 1009: Comprehensive ctDNA sequencing reveals mechanisms of resistance to rociletinib in EGFR T790M-mutated NSCLC
Background: First and second-generation EGFR tyrosine kinase inhibitors (TKIs) have benefited patients with EGFR-mutated non… 
2016
2016
Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer
Survivin is an anti-apoptotic protein that is implicated in the regulation of apoptosis and cell cycle in various types of… 
2015
2015
Cross-reactivity of EGFR Mutation-specific Immunohistochemistry Assay in HER2-positive Tumors
The coexpression of HER2 and EGFR L858R in a solitary nodule removed from the lung, whose mutation was not confirmed by molecular… 
2015
2015
Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma
Epidermal growth factor receptor (EGFR) mutation status is the best predictor of patient response to treatments with tyrosine… 
2015
2015
T6 MET targeted therapy in Lung adenocarcinoma: Does ‘Resistant’ EGFR make a MET-responsive dimer?
Introduction Lung cancer has extremely poor survival with few effective treatments. Activating EGFR mutations (e.g. L858R… 
2012
2012
EGFR-TKI一线治疗EGFR基因突变的晚期非小细胞肺癌临床观察
背景与目的 研究表明，一线表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI）治疗晚期非小细胞肺癌（non-small cell lung… 
2012
2012
[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion…
OBJECTIVE To investigate the gene mutation of EGFR and KRAS in Chinese patients with non-small cell lung cancer (NSCLC), and to… 
2011
2011
EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients
Purpose: To assess whether polymorphisms of genes related to estrogen biosynthesis and metabolism are associated with EGFR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)